Research Article
MicroRNA-19a Targets Fibroblast Growth Factor-Inducible Molecule 14 and Prevents Tubular Damage in Septic AKI
Figure 4
miR-19a protects mice from septic AKI. (a) RT-qPCR analysis examining Fn14 mRNA expression in kidney tissues from CLP-treated mice with negative control (NC) or miR-19a mimic (miR-19a) delivery (). and versus NC, one-way ANOVA, post hoc comparisons, and Tukey’s test. (b) Western blotting analyses comparing the levels of Fn14 protein in kidney tissues from CLP-treated mice with negative control (NC) or miR-19a mimic (miR-19a) delivery (). (c) Representative H&E and IHC as well as TUNEL staining images for Fn14, KIM-1, and TUNEL in kidney tissues from CLP-treated mice with negative control (NC) or miR-19a mimic (miR-19a) delivery. (d) Tubular damage score of kidney tissues from CLP-treated mice with negative control (NC) or miR-19a mimic (miR-19a) delivery (). One-way ANOVA, post hoc comparisons, and Tukey’s test. V: vehicle. (e) Western blotting analyses detecting the cleavage of caspase-3 in kidney tissues from CLP-treated mice with negative control (NC) or miR-19a mimic (miR-19a) delivery. (f–h) Serum creatinine (f), blood urea nitrogen (BUN) (g), and lactate (h) levels in kidney tissues from CLP-treated mice with negative control (NC) or miR-19a mimic (miR-19a) delivery (). One-way ANOVA, post hoc comparisons, and Tukey’s test. V: vehicle.
(a) |
(b) |
(c) |
(d) |
(e) |
(f) |
(g) |
(h) |